Reviva Pharmaceuticals EBITDA vs. Cash Per Share
| RVPH Stock | USD 1.24 0.10 8.77% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -39.5 T | Current Value -37.5 T | Quarterly Volatility 13.6 T |
For Reviva Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Reviva Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Reviva Pharmaceuticals Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Reviva Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Reviva Pharmaceuticals Holdings over time as well as its relative position and ranking within its peers.
Reviva |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Reviva Pharmaceuticals Cash Per Share vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Reviva Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reviva Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Reviva Pharmaceuticals Holdings is rated below average in ebitda category among its peers. It is rated below average in cash per share category among its peers . As of now, Reviva Pharmaceuticals' EBITDA is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Reviva Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Reviva Cash Per Share vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Reviva Pharmaceuticals |
| = | (39.5 T) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Reviva Pharmaceuticals |
| = | 1.13 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Reviva Cash Per Share Comparison
Reviva Pharmaceuticals is currently under evaluation in cash per share category among its peers.
Reviva Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Reviva Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Reviva Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Reviva Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Reviva Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -49.1 M | -51.5 M | |
| Net Loss | -21.9 M | -20.8 M | |
| Income Tax Expense | -16.9 B | -16.1 B | |
| Net Interest Income | 499 K | 523.9 K | |
| Interest Income | 499 K | 523.9 K | |
| Operating Income | -39.5 T | -37.5 T | |
| Net Loss | -39.3 M | -37.3 M | |
| Income Before Tax | -39.2 M | -37.3 M | |
| Total Other Income Expense Net | 39.5 T | 41.5 T | |
| Net Loss | -39.3 M | -37.3 M | |
| Change To Netincome | 334.3 K | 218.1 K | |
| Net Loss | -1.6 M | -1.6 M | |
| Income Quality | 0.72 | 0.62 | |
| Net Income Per E B T | 1 M | 1.1 M |
Reviva Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Reviva Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Reviva Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Reviva Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Reviva Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Use Investing Themes to Complement your Reviva Pharmaceuticals position
In addition to having Reviva Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
To fully project Reviva Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Reviva Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Reviva Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.